Skip to main content Accessibility help
×
Home

Hypofractionated intensity-modulated radiation therapy with concurrent cisplatin in locally advanced oropharyngeal cancer: feasibility experience from a Government cancer centre of Eastern India in a resource-constrained setting

  • Srikrishnadevarayulu Rangineni (a1), Debarshi Lahiri (a1), Biplab Misra (a1), Tapas Maji (a1), Sanjoy Roy (a1), Dilip Kumar Ray (a1), Saptarshi Banerjee (a1), Subhadip Das (a1) and Ashwin Mohandas Pallath (a1)...

Abstract

Purpose:

Radiation therapy (RT), in combination with chemotherapy, is the mainstay in the treatment for locally advanced oropharyngeal cancer. We analysed the tumour response and the toxicity profiles in patients having locally advanced oropharyngeal cancers receiving hypofractionated intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with Cisplatin investigating the feasibility and radiobiological efficacy of the regimen, along with its use as a resource-sparing alternative for a high-volume centre.

Material and Methods:

The records of 41 eligible patients with locally advanced squamous cell carcinoma of oropharynx, registered from September 2015 to April 2017, treated with hypofractionated IMRT with concurrent Cisplatin, were analysed from the hospital database. Patients received concurrent chemo-radiation with 2 cycles of 3-weekly cisplatin on day 1 and day 22 along with hypofractionated IMRT, 55 Gy delivered in 20 fractions over 4 weeks. Patients were observed for any radiation reaction or chemotherapy toxicity at least once a week during the course of radiation therapy.

Results:

Twenty-nine patients (70·7%) achieved complete response and remaining 12 showed partial response. Acute grade 3 toxicity was observed mostly in the form of oral mucositis and radiation dermatitis. Both grade 3 oral mucositis and radiation dermatitis were seen in 15 patients (36·6%) and 7 patients (17%), respectively. The most common late toxicities were dysphagia and dry mouth. Twenty-five patients (61%) completed the overall treatment within 4 weeks’ duration.

Conclusion:

This hypofractionated regimen is feasible and was associated with tolerable acute and late morbidity and satisfactory locoregional response. Larger prospective, multi- institutional studies examining similar schedules may be undertaken to establish this as a standard practice, particularly for a high-volume centre.

Copyright

Corresponding author

Author for correspondence: Debarshi Lahiri, Chittaranjan National Cancer Institute Kolkata, India. E-mail: debarshil@gmail.com

References

Hide All
1. Bray, F, Ferlay, J, Soerjomataram, I,Siegel, R L, Torre, L A, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394424.
2. Dische, S, Saunders, M, Barrett, A. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123136.
3. Bentzen, S M, Saunders, M I, Dische, S. Repair half-times estimated from observations of treatment-related morbidity after CHART. Radiother Oncol 1999; 53: 219226.
4. Bentzen, S M, Saunders, M I, Dische, S. Radiotherapy related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduce from the CHART trial. Radiother Oncol 2001; 60: 123135.
5. Landuyt, W, Fowler, J, Ruifrokb, A, Stiiben, G, van der Kogeld, A, van der Schuerena, E. Kinetics of repair in the spinal cord of the rat. Radiother Oncol 1997;45 (1): 5562.
6. Overgaard, J, Hansen, H S, Specht, L. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomisedcontrolled trial. Lancet 2003; 362: 933940.
7. Bourhis, J, Lapeyre, M, Tortochaux, J. Phase III randomized trial of very accelerated compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006; 24: 28732878.
8. Fowler, J F, Harari, P. Confirmation of improved local-regional control with altered fractionation in head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48: 36.
9. Withers, H R, Peters, L J. Transmutability of dose and time. Commentary on the first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 12.
10. Hall, E. Radiobiology for the Radiologist, 7th edition. Philadelphia: Wolters Kluwer, 2012: 401403.
11. Denis, F, Garaud, P, Bardet, E. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 6976.
12. Brizel, D M, Albers, M E, Fisher, S R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 17981804.
13. Bernier, J, Domenge, C, Ozsahin, M. Postoperative irradiation with or without concomitant chemotherapy for locallyadvanced head and neck cancer. N Engl J Med 2004; 350: 19451952.
14. Semrau, R, Mueller, R P, Stuetzer, H. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5 fluorouracil: updated results of a randomized multicentric trial in advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 13081316.
15. Budach, V, Stuschke, M, Budach, W. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycinis more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J ClinOncol 2005; 23: 11251135.
16. Pignon, J P, Bourhis, J, Domenge, C, Designé, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949955.
17. Pignon, J P, le Maître, A, Maillard, E, Bourhis, J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 414.
18. Kasibhatla, M, Kirkpatrick, J P, Brizel, D M. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2007; 68: 14911495.
19. Fowler, J. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2008; 71: 326329.
20. Fowler, J. Practical time-dose evaluation, or how to stop worrying and love LQ. In: Levitt, SH, Purdy, JA, Perez, CA, Poortmans, P (eds). Technical Basis of Radiation Therapy, 5th revised edition. Heidelberg: Springer-Verlag, 2012: 946.
21. Ebookpdf.com. Ajcc 7th edition 2010.pdf ‒ free download. 2019. [online] Available at: https://ebookpdf.com/ajcc-7th-edition-2010
22. ECOG-ACRIN. Spring 2017 group meeting – ECOG-ACRIN. 2019. [online] Available at: https://ecog-acrin.org/resources/group-%20meetings/spring-2017-group-meeting
23. Ctep.cancer.gov. 2019. [online] Available at: https://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf
25. Overgaard, J, Hansen, H S, Specht, L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 & 7 randomized control trial. Lancet 2003; 362: 933940.
26. Benghiat, H, Sanghera, P, Cashmore, J, Hodson, J, Mehanna, H, Simmons, R, et al. Four week hypofractionated accelerated intensity modulated radiotherapy and synchronous carboplatin or cetuximab in biologically staged oropharyngeal carcinoma. Cancer Clin Oncol 2014; 3 (2). doi: 10.5539/cco.v3n2p1
27. Chan, A K., Sanghera, P, Choo, B A, et al. Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 2011; 23 (1): 3439.
28. Meduri, B, D’Angelo, E, Barbieri, P, et al. EP-1089: accelerated hypofractionated IMRT-IGRT and concurrent chemotherapy in oropharyngeal cancer. Radiother Oncol 2016; 119: S524.
29. Sanghera, P, McConkey, C, Ho, K F, Glaholm, J, Hartley, A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007; 67: 13421351.

Keywords

Hypofractionated intensity-modulated radiation therapy with concurrent cisplatin in locally advanced oropharyngeal cancer: feasibility experience from a Government cancer centre of Eastern India in a resource-constrained setting

  • Srikrishnadevarayulu Rangineni (a1), Debarshi Lahiri (a1), Biplab Misra (a1), Tapas Maji (a1), Sanjoy Roy (a1), Dilip Kumar Ray (a1), Saptarshi Banerjee (a1), Subhadip Das (a1) and Ashwin Mohandas Pallath (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed